STOCK TITAN
  1. Home
  2. Sec-filings
  3. ATAI
  4. [Form 4] ATAI Life Sciences N.V. Insider Trading Activity

ATAI insider reports 7.7M shares acquired and option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Atai Beckley N.V. (ATAI) reported an insider transaction: a director acquired 7,702,990 common shares on November 5, 2025. The filing notes this occurred in connection with the Issuer’s completion of its acquisition of Beckley Psytech, for which an aggregate of 103,000,066 common shares were issued as consideration or as underlying replacement awards.

The director also received two stock option grants with a $4.48 exercise price, covering 103,000 and 40,400 shares, each expiring on November 5, 2035. One option vests in full on the first anniversary of the grant date, and the other vests in 12 substantially equal monthly installments beginning December 5, 2025. Following the transactions, the director held 7,702,990 common shares directly.

Positive

  • None.

Negative

  • None.

Insights

Large share receipt tied to M&A; routine option grants.

The director reported acquisition of 7,702,990 ATAI common shares on November 5, 2025, tied to the closing of the Beckley Psytech deal where an aggregate of 103,000,066 shares were issued as consideration or replacement awards. This indicates equity issued to target stakeholders at closing.

Two options were granted at an exercise price of $4.48, covering 103,000 and 40,400 shares, expiring on November 5, 2035. Vesting terms are standard: one cliff on the first anniversary; one monthly over 12 installments starting December 5, 2025. Actual impact depends on future exercise and sale decisions by the holder.

Insider Feilding-Mellen Cosmo
Role Director
Type Security Shares Price Value
Grant/Award Stock Option 103,000 $0.00 --
Grant/Award Stock Option 40,400 $0.00 --
Grant/Award Common Shares 7,702,990 $0.00 --
Holdings After Transaction: Stock Option — 103,000 shares (Direct); Common Shares — 7,702,990 shares (Direct)
Footnotes (1)
  1. On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement. The stock option shall vest in full on the first anniversary of the grant date. The stock option shall vest in 12 substantially equal monthly installments, beginning on December 5, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feilding-Mellen Cosmo
(Last) (First) (Middle)
C/O ATAI BECKLEY N.V.
PROF. J.H. BAVINCKLAAN 7
(Street)
AMSTERDAM P7 1183AT
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Atai Beckley N.V. [ ATAI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 11/05/2025 A 7,702,990 A (1) 7,702,990 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $4.48 11/05/2025 A 103,000 (2) 11/05/2035 Common Shares 103,000 $0 103,000 D
Stock Option $4.48 11/05/2025 A 40,400 (3) 11/05/2035 Common Shares 40,400 $0 40,400 D
Explanation of Responses:
1. On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement.
2. The stock option shall vest in full on the first anniversary of the grant date.
3. The stock option shall vest in 12 substantially equal monthly installments, beginning on December 5, 2025.
/s/ Ryan Barrett, as attorney in fact 11/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ATAI report?

A director acquired 7,702,990 common shares on November 5, 2025, reported as an acquisition of beneficial ownership.

How does the Beckley Psytech acquisition relate to ATAI shares?

At closing, ATAI issued an aggregate of 103,000,066 common shares as consideration or underlying replacement awards.

What stock options were granted to the ATAI director?

Two options with a $4.48 exercise price covering 103,000 and 40,400 shares, expiring November 5, 2035.

What are the vesting schedules for the options?

One vests in full on the first anniversary of grant; the other vests in 12 equal monthly installments starting December 5, 2025.

How many ATAI shares did the director hold after the transaction?

The filing shows 7,702,990 common shares directly beneficially owned after the reported transaction.

What is the ownership role of the reporting person at ATAI?

The reporting person is a Director of Atai Beckley N.V.